Related Experiment Video
Updated: Jun 7, 2026
A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
Published on: November 10, 2008
Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice
Diego Piedrahita1, Israel Hernández, Alejandro López-Tobón
1Cellular and Molecular Neurobiology Area, Viral Vector Core and Gene Therapy, Group of Neuroscience of Antioquia, Faculty of Medicine, Sede de Investigación Universitaria, University of Antioquia, AA 1226 Medellin, Colombia.
Abstract:
Alzheimer's disease is a major cause of dementia for which treatments remain unsatisfactory. Cyclin-dependent kinase 5 (CDK5) is a relevant kinase that has been hypothesized to contribute to the tau pathology. Several classes of chemical inhibitors for CDK5 have been developed, but they generally lack the specificity to distinguish among various ATP-dependent kinases. Therefore, the efficacy of these compounds when tested in animal models cannot definitively be attributed to an effect on CDK5. However, RNA interference (RNAi) targeting of CDK5 is specific and can be used to validate CDK5 as a possible treatment target. We delivered a CDK5 RNAi by lentiviral or adenoassociated viral vectors and analyzed the results in vitro and in vivo. Silencing of CDK5 reduces the phosphorylation of tau in primary neuronal cultures and in the brain of wild-type C57BL/6 mice. Furthermore, the knockdown of CDK5 strongly decreased the number of neurofibrillary tangles in the hippocampi of triple-transgenic mice (3×Tg-AD mice). Our data suggest that this downregulation may be attributable to the reduction of the CDK5 availability in the tissue, without affecting the CDK5 kinase activity. In summary, our findings validate CDK5 as a reasonable therapeutic target for ameliorating tau pathology.
Insights
Cyclin-dependent kinase 5 (CDK5) silencing reduces tau pathology in Alzheimer's disease models. This validates CDK5 as a therapeutic target for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) is a leading cause of dementia with limited treatment options.
- Tau pathology is a hallmark of AD, and Cyclin-dependent kinase 5 (CDK5) is implicated in its development.
- Existing chemical inhibitors for CDK5 lack specificity, complicating target validation.
Purpose of the Study:
- To validate CDK5 as a specific therapeutic target for Alzheimer's disease.
- To investigate the efficacy of RNA interference (RNAi) for targeting CDK5 in AD models.
- To assess the impact of CDK5 knockdown on tau phosphorylation and neurofibrillary tangles.
Main Methods:
- Delivery of CDK5 RNAi using lentiviral and adeno-associated viral vectors.
- In vitro studies using primary neuronal cultures.
- In vivo studies in wild-type C57BL/6 mice and triple-transgenic AD (3×Tg-AD) mice.
Main Results:
- CDK5 silencing significantly reduced tau phosphorylation in neuronal cultures and mouse brains.
- Knockdown of CDK5 markedly decreased neurofibrillary tangle formation in the hippocampi of 3×Tg-AD mice.
- Reduced CDK5 availability, not altered kinase activity, was associated with therapeutic effects.
Conclusions:
- CDK5 is a validated therapeutic target for ameliorating tau pathology in Alzheimer's disease.
- RNAi-mediated silencing of CDK5 offers a specific approach to target this kinase.
- These findings support the development of novel therapeutics targeting CDK5 for AD treatment.
